Cargando…

Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model

Cav1.2 channels are an L-type voltage-dependent Ca(2+) channel, which is specifically blocked by calcium antagonists. Voltage-dependent Ca(2+) channels are generally considered to be functional only in excitable cells like neurons and muscle cells, but recently they have been reported to also be fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinshuang, Saegusa, Hironao, Huntula, Soontaraporn, Tanabe, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591481/
https://www.ncbi.nlm.nih.gov/pubmed/31235768
http://dx.doi.org/10.1038/s41598-019-45681-3
_version_ 1783429742162083840
author Wang, Xinshuang
Saegusa, Hironao
Huntula, Soontaraporn
Tanabe, Tsutomu
author_facet Wang, Xinshuang
Saegusa, Hironao
Huntula, Soontaraporn
Tanabe, Tsutomu
author_sort Wang, Xinshuang
collection PubMed
description Cav1.2 channels are an L-type voltage-dependent Ca(2+) channel, which is specifically blocked by calcium antagonists. Voltage-dependent Ca(2+) channels are generally considered to be functional only in excitable cells like neurons and muscle cells, but recently they have been reported to also be functional in non-excitable cells like microglia, which are key players in the innate immune system and have been shown to be involved in the pathophysiology of Parkinson’s disease. Here, we show that Cav1.2 channels are expressed in microglia, and that calcium antagonists enhanced the neuroinflammatory M1 transition and inhibited neuroprotective M2 transition of microglia in vitro. Moreover, intensive degeneration of dopaminergic neurons and accompanying behavioural deficits were observed in microglia-specific Cav1.2 knockdown mice intoxicated with MPTP, a neurotoxin that induces Parkinson’s disease-like symptoms, suggesting detrimental effects of microglial Cav1.2 blockade on Parkinson’s disease. Therefore, microglial Cav1.2 channel may have neuroprotective roles under physiological conditions and may also contribute to recovery from disease conditions.
format Online
Article
Text
id pubmed-6591481
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65914812019-07-02 Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model Wang, Xinshuang Saegusa, Hironao Huntula, Soontaraporn Tanabe, Tsutomu Sci Rep Article Cav1.2 channels are an L-type voltage-dependent Ca(2+) channel, which is specifically blocked by calcium antagonists. Voltage-dependent Ca(2+) channels are generally considered to be functional only in excitable cells like neurons and muscle cells, but recently they have been reported to also be functional in non-excitable cells like microglia, which are key players in the innate immune system and have been shown to be involved in the pathophysiology of Parkinson’s disease. Here, we show that Cav1.2 channels are expressed in microglia, and that calcium antagonists enhanced the neuroinflammatory M1 transition and inhibited neuroprotective M2 transition of microglia in vitro. Moreover, intensive degeneration of dopaminergic neurons and accompanying behavioural deficits were observed in microglia-specific Cav1.2 knockdown mice intoxicated with MPTP, a neurotoxin that induces Parkinson’s disease-like symptoms, suggesting detrimental effects of microglial Cav1.2 blockade on Parkinson’s disease. Therefore, microglial Cav1.2 channel may have neuroprotective roles under physiological conditions and may also contribute to recovery from disease conditions. Nature Publishing Group UK 2019-06-24 /pmc/articles/PMC6591481/ /pubmed/31235768 http://dx.doi.org/10.1038/s41598-019-45681-3 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wang, Xinshuang
Saegusa, Hironao
Huntula, Soontaraporn
Tanabe, Tsutomu
Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title_full Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title_fullStr Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title_full_unstemmed Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title_short Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model
title_sort blockade of microglial cav1.2 ca(2+) channel exacerbates the symptoms in a parkinson’s disease model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591481/
https://www.ncbi.nlm.nih.gov/pubmed/31235768
http://dx.doi.org/10.1038/s41598-019-45681-3
work_keys_str_mv AT wangxinshuang blockadeofmicroglialcav12ca2channelexacerbatesthesymptomsinaparkinsonsdiseasemodel
AT saegusahironao blockadeofmicroglialcav12ca2channelexacerbatesthesymptomsinaparkinsonsdiseasemodel
AT huntulasoontaraporn blockadeofmicroglialcav12ca2channelexacerbatesthesymptomsinaparkinsonsdiseasemodel
AT tanabetsutomu blockadeofmicroglialcav12ca2channelexacerbatesthesymptomsinaparkinsonsdiseasemodel